H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros (OMER) today and set a price target of $32.00. The company’s shares closed last Friday at $11.44.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 18.4% and a 57.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Biospecifics Technologies, and Springworks Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros with a $21.50 average price target, representing an 82.4% upside. In a report issued on November 10, Maxim Group also assigned a Buy rating to the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.46 and a one-year low of $8.50. Currently, Omeros has an average volume of 999.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
